Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.

Cystic fibrosis (CF) lung disease starts early in life and progresses throughout infancy and the preschool years (1, 2). Therapeutic strategies initiated early in life have the potential to reverse this process and maintain lung health. Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that increases the channel’s opening probability. Remarkable and sustained lung function improvements have been demonstrated in patients aged 6 years and older with gating CFTR mutations such as G551D on at least one allele (3, 4). A recent open-label trial provided evidence for safety and nutritional benefits in children aged 2–5 years, but lung function was not systematically assessed within this study (5). The lung clearance index (LCI) measured by multiple-breath washout has been shown to be a sensitive measure to capture lung function abnormalities in patients with CF and is feasible for use in preschool children because it requires minimal cooperation. LCI can also be used to detect treatment effects in interventional trials (6, 7). As part of GOAL (G551D Observational Study) (NCT 01521338), a multicenter longitudinal observational study to explore biomarkers as well as clinical and physiological characteristics of patients with CF with gating mutations initiated on ivacaftor therapy (8), we report the results of LCI in preschool patients assessed before and after ivacaftor treatment initiation. Multiple-breath washout measurements based on nitrogen as the tracer gas using the EXHALYZER D (Eco Medics) were performed in preschool children with CF aged 3 to 5 years. Measurements were performed in accordance with recently published standards for preschool children (9) and modifications of the equipment to reduce dead space as described previously (2). Baseline was defined as the predose measurement immediately preceding the start of treatment; all other medications were kept constant throughout the study period. Changes in LCI from baseline to 1 month and from baseline to 6 months after the start of ivacaftor treatment were analyzed using nonparametric Wilcoxon signed-rank tests. Relative changes in LCI compared with baseline were evaluated using one-sample Kolmogorov-Smirnov tests. This analysis includes five subjects with CF enrolled in the GOAL study in the United States and an additional four preschoolaged patients with CF started on ivacaftor at the Hospital for Sick Children in Toronto (SickKids). Baseline characteristics of the study population are displayed in Table 1. Median sweat chloride concentration at baseline was 103 mEq/L. All nine patients carried one copy of the G551D mutation, with seven patients being compound heterozygous for F508del. The average LCI at baseline was 10.6 (interquartile range [IQR], 8.9 to 11.2); seven of nine patients had LCI values above the upper limit of normal, reflecting increased ventilation inhomogeneity (2) (Figure 1A). Mean sweat chloride concentrations decreased to 46 mEq/L 1 month after ivacaftor initiation (mean change [IQR],256 [261 to 247]). Within-patient LCI significantly improved 1 month after the first dose of ivacaftor (median LCI at 1 mo, 7.10 [6.6 to 8.5]; P = 0.02). The improvement in LCI was maintained 6 months after the first dose (median LCI, 7.3 [7.3 to 7.6]; P = 0.03). Assessing relative changes in LCI at 1 month and 6 months after ivacaftor treatment yielded similar results. LCI significantly improved from baseline at both 1 month (median change in LCI from baseline, 223.6% [IQR, 234.2 to 220.2]; P, 0.001) and 6 months post-treatment (median change in LCI from baseline, 224.6% [IQR, 231.4 to 220.4]; P, 0.001). Thus, rapid and sustained improvements in LCI were demonstrated with ivacaftor therapy that exceeded the between-test reproducibility and thus the physiologically relevant change for quarterly LCI measurements in health, which we recently demonstrated to be 15% in preschool children (10). The only two patients not showing an improvement in LCI had normal baseline values of LCI. The observed effect size was similar to what has been described in older patients with CF treated with ivacaftor (6, 11). This study also supports the concept that LCI is a suitable outcome measure to capture changes in lung function in preschool children on CFTR modulator therapy, and also that ivacaftor helps improve early airway disease even in young children. n